Welcome to our dedicated page for Catheter Precision news (Ticker: VTAK), a resource for investors and traders seeking the latest updates and insights on Catheter Precision stock.
Catheter Precision Inc. (VTAK) delivers innovative electrophysiology solutions through its VIVO cardiac mapping system and LockeT vascular closure technology. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments in non-invasive cardiac care.
Investors and medical professionals will find curated press releases covering regulatory milestones, product innovations, and partnership agreements. Our repository includes updates on FDA clearances, international distribution expansions, and peer-reviewed study results validating device efficacy.
Key content categories include quarterly financial results, technology enhancements to the VIVO 3D imaging platform, and clinical outcomes data for the suture retention system. All materials maintain compliance with financial disclosure regulations while emphasizing patient-centered innovation in arrhythmia treatment.
Bookmark this page for real-time updates on Catheter Precision's advancements in electrophysiology and vascular closure solutions. Visit regularly to stay informed about developments impacting cardiac care technology and investment considerations.
Catheter Precision, Inc. (VTAK) has received a purchase order for LockeT, its newest product, from the University of California San Diego (UCSD) health system. This order allows for product evaluations at the hospital to begin. CEO David Jenkins emphasized the importance of hospitals evaluating products before committing to long-term purchases. VP Robert Locke praised UCSD as an early adopter of new technologies in electrophysiology.
Catheter Precision, Inc. (NYSE American: VTAK) released its Q1 2024 financials and operational report, highlighting key achievements and financial results. The company showcased progress in product development, clinical studies, and market expansion activities, along with a focus on talent acquisition to support future growth. With a solid financial position and a clear strategy, Catheter Precision aims to drive innovation in the field of cardiac electrophysiology.
Catheter Precision, Inc. (NYSE-American: VTAK) announces Marie-Claude Jacques as the new Chief Commercial Officer. With a background in successful sales leadership at Baylis Medical and Boston Scientific, Jacques aims to drive growth and success for Catheter Precision.
FAQ
What is the current stock price of Catheter Precision (VTAK)?
What is the market cap of Catheter Precision (VTAK)?
